Key result
Mitral regurgitation is not associated with ischemic stroke or thromboembolism in atrial fibrillation.
Why the study?
Although significant mitral regurgitation has been suggested to protect against stroke in patients with nonrheumatic AF, its actual effect on stroke and thromboembolic risk in AF remains controversial.
Cohort (n=8,675)
Yes
Answers are grounded in this paper and cite their sources.
Does not support incorporating mitral regurgitation into atrial fibrillation thromboembolic risk assessment; leaves open its value in updated models.
March 2019 1 A new classification has recently been proposed and validated for atrial fibrillation (AF) patients with valvular heart disease.1,2 Mitral regurgitation (MR) is included in EHRA (European Heart Rhythm Association) Type 2 valvular heart disease, which refers to AF patients with valvular heart disease needing therapy with a vitamin K antagonist or a nonvitamin K antagonist oral anticoagulant, also taking into consideration the CHA2DS2-VASc score. 1 It has been suggested that significant MR might actually be protective against left atrial spontaneous echo contrast formation and against stroke in patients with nonrheumatic AF.3 However, the effect of MR on the risk of stroke in patients with AF is still controversial. We, therefore, studied whether or not MR was associated with a lower risk of thromboembolic events in a large series of patients with AF and whether MR may be independently associated with a different risk of thromboembolic events beyond the recognized items of the CHA2DS2-VASc score in AF patients. All patients with AF between 2000 and 2010 seen in the cardiology department in our public institution (academic hospital, tertiary referral center) were retrospectively identified and followed until December 2010.4 We collected information on type of AF, primary diagnoses and coexisting conditions, performed procedures, medication at discharge and in-hospital cardiovascular events and death (1 institution with 4 different sites, all specialties). Patients with prosthetic valve or mitral stenosis were excluded of the analysis, significant left-sided valvular heart diseases were identified (mild, moderate, or severe) and classified as severe or non severe based on the European Society of Cardiology guidelines.5 Severe MR was described by a vena contracta width ≥7 mm, effective regurgitant orifice area ≥40 mm2 and regurgitant volume ≥60 mL/beat calculated on a proximal isovelocity surface area. See the Data Supplement for details related to the methods. Among 8675 patients with AF 838 patients (10%) had MR, among whom 135 (16%) had severe MR. When comparing patients with MR or no MR (Table), patients with MR were older than patients with no MR, had higher CHA2DS2-VASc score, and more frequent permanent AF, heart failure, and vitamin K antagonist use. During a mean follow-up of 2.5 years (median 1.2, interquartile range 4.2), 688 ischemic stroke (IS)/thromboembolic events were recorded. MR was associated with a nonsignificant higher risk for IS/thromboembolic events (hazard ratio, 1.09; 95% CI, 0.86–1.39; P=0.47). After adjustment for anticoagulant and antiplatelet use, CHA2DS2-VASc and HAS-BLED scores, patients with MR tended to have a higher all-cause and cardiovascular mortality but had a similar risk of IS/ thromboembolic events when compared with patients with no MR (Table; Table in the Data Supplement). Severe MR was also associated with a similar risk for IS/ thromboembolic events when compared with other AF patients (adjusted hazard ratio, 0.94; 95% CI, 0.49–1.81; P=0.85). In the 2 groups with MR or no MR, IS/thromboembolic risk increased with higher CHA2DS2-VASc scores. FacSPECIAL REPORT
No takes yet. Share an insight, caveat, or question.
Bisson et al. (2019) conducted a cohort in Atrial fibrillation (n=8,675). Mitral regurgitation vs. No mitral regurgitation was evaluated on Ischemic stroke or thromboembolic events (HR 1.09, 95% CI 0.86-1.39, p=0.47). Mitral regurgitation in patients with atrial fibrillation was not associated with ischemic stroke or thromboembolic events.
Synapse has enriched 10 related papers. Consider them for comparative context: